Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
12 juil. 2016 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference
26 mai 2016 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief...
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin
31 mars 2016 16h03 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from...
Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
05 janv. 2016 07h05 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced an update from its 28 day...